CA2231332A1 - Bacterial delivery system - Google Patents

Bacterial delivery system

Info

Publication number
CA2231332A1
CA2231332A1 CA002231332A CA2231332A CA2231332A1 CA 2231332 A1 CA2231332 A1 CA 2231332A1 CA 002231332 A CA002231332 A CA 002231332A CA 2231332 A CA2231332 A CA 2231332A CA 2231332 A1 CA2231332 A1 CA 2231332A1
Authority
CA
Canada
Prior art keywords
delivery system
bacterial delivery
bacterial
shigella
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002231332A
Other languages
French (fr)
Other versions
CA2231332C (en
Inventor
Arthur A. Branstrom
Donata R. Sizemore
Jerald C. Sadoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Army
Original Assignee
Arthur A. Branstrom
Donata R. Sizemore
Jerald C. Sadoff
The United States Of America As Represented By The Secretary Of The Army , Walter Reed Army Institute Of Research (Wrair)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/523,855 external-priority patent/US5824538A/en
Application filed by Arthur A. Branstrom, Donata R. Sizemore, Jerald C. Sadoff, The United States Of America As Represented By The Secretary Of The Army , Walter Reed Army Institute Of Research (Wrair) filed Critical Arthur A. Branstrom
Publication of CA2231332A1 publication Critical patent/CA2231332A1/en
Application granted granted Critical
Publication of CA2231332C publication Critical patent/CA2231332C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to a method of introducing functional nucleic acids into cells using a bacterial delivery system. The delivery system can be used as a vaccine to prevent or treat infectious diseases. This invention can be applied to any desired bacteria including attenuated strains of Shigella.
CA002231332A 1995-09-06 1996-09-06 Bacterial delivery system Expired - Fee Related CA2231332C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US331895P 1995-09-06 1995-09-06
US08/523,855 1995-09-06
US60/003,318 1995-09-06
US08/523,855 US5824538A (en) 1995-09-06 1995-09-06 Shigella vector for delivering DNA to a mammalian cell
US1803596P 1996-05-21 1996-05-21
US60/018,035 1996-05-21
PCT/US1996/014190 WO1997008955A1 (en) 1995-09-06 1996-09-06 Bacterial delivery system

Publications (2)

Publication Number Publication Date
CA2231332A1 true CA2231332A1 (en) 1997-03-13
CA2231332C CA2231332C (en) 2007-04-17

Family

ID=27357382

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002231332A Expired - Fee Related CA2231332C (en) 1995-09-06 1996-09-06 Bacterial delivery system

Country Status (6)

Country Link
EP (1) EP0881884A4 (en)
JP (1) JP2000500734A (en)
AU (1) AU731061B2 (en)
CA (1) CA2231332C (en)
IL (1) IL123569A (en)
WO (1) WO1997008955A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286210A1 (en) * 1997-04-18 1998-10-29 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Attenuated salmonella strain used as a vehicle for oral immunization
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CN1253551C (en) 1997-09-10 2006-04-26 维昂药品公司 Genetically modified tumor-targeted bacteria with reduced virulence
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
JP2001519162A (en) 1997-10-07 2001-10-23 ユニバーシティ・オブ・メリーランド・バイオテクノロジー・インスティチュート Method for introducing and expressing RNA in animal cells
DE19754938B4 (en) 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC method for induction of targeted, somatic transgenicity
US6825028B1 (en) * 1998-12-11 2004-11-30 Christoph Von Eichel-Streiber Recombinant listeria
US6143551A (en) * 1997-12-29 2000-11-07 Schering Aktiengesellschaft Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
CU22661A1 (en) * 1997-12-30 2001-04-27 Cnic Ct Nac Investigaciones NEW VACCINE CANDIDATES OF VIBRIO CHOLERAE AND METHOD OF OBTAINING
US6596477B1 (en) 1998-09-28 2003-07-22 University Of Maryland Biotechnology Institute Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1261369A4 (en) * 1999-10-04 2006-02-01 Vion Pharmaceuticals Inc Compositions and methods for tumor-targeted delivery of effector molecules
JP2008521434A (en) * 2004-11-30 2008-06-26 エーラス グローバル ティービー ワクチン ファウンデーション Bacterial packaging strains useful for the production and production of recombinant double-stranded RNA nucleocapsids (rdsRNs) and their use
AU2005316458B2 (en) * 2004-12-17 2011-04-07 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease
AR242989A1 (en) * 1988-07-15 1993-06-30 Inst Pasteur I Nat De La Sante A method for modifying a wild strain of a "shigella", in order to produce a modified strain suitable for preparing a vaccine against the wild strain, and a "shigella" strain thus modified.

Also Published As

Publication number Publication date
CA2231332C (en) 2007-04-17
AU7105996A (en) 1997-03-27
JP2000500734A (en) 2000-01-25
EP0881884A1 (en) 1998-12-09
IL123569A (en) 2006-10-05
AU731061B2 (en) 2001-03-22
EP0881884A4 (en) 2004-07-14
IL123569A0 (en) 1998-10-30
WO1997008955A1 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
CA2231332A1 (en) Bacterial delivery system
AU4802896A (en) Phosphonomonoester nucleic acids, process for their preparation, and their use
AU5370096A (en) Method of treating or preventing non-viral microbial infection
AU5887296A (en) Process for the transcriptionless amplification of nucleic aids
CA2190324A1 (en) Method and Composition for Inhibiting Growth of Microorganisms Including Peracetic Acid and a Non-Oxidizing Biocide
ATE219499T1 (en) LIPOPEPTIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
AU7508794A (en) Novel lipase, microorganism producing the lipase, process for producing the lipase, and use of the lipase
AU5450998A (en) Methods for controlling above-ground plant diseases using antibiotic-producing strains of (bacillus sp.)
AU3745395A (en) Microorganisms as therapeutic delivery systems
CA2344166A1 (en) Compositions of .beta.-glucans and specific igiv
AU4370396A (en) Gram negative bacterial infection vaccine
BG102312A (en) New derivatives of 5-oxy-deoaminyl 6-oxy-methyl erythronolide a, method for their preparation and application for the preparation of biologically active products
AU5174596A (en) Fatty acid based compositions and methods for the control of plant infections and pests
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
AU4083096A (en) Process for deactivating or destroying microorganisms
WO2001040280A3 (en) Composition and method for treating a microbial infection
MD960242A (en) Microorganisms for biological control of plants diseases
CA2148563A1 (en) Purified nontypable haemophilus influenzae p5 protein as a vaccine for nontypable haemophilus influenzae strain
CA2029201A1 (en) Process for purifying b pertussis antigens
EP0970962A3 (en) Process for preparing 2,2-difluoroketene silyl, 0, S-acetals and alpha,alpha-difluoro-beta-silyloxy-1,3-dioxolane-4-propanoic acid 0,S-esters
AU2548597A (en) Antibodies against avirulence/pathogenicity proteins of plant pathogens
WO2001047962A8 (en) Attenuated microorganisms for the treatment of infection
EP1574579A3 (en) Outer surface proteins, their genes, and their use
DE68913128T2 (en) Process for the preparation of L-alanine dehydrogenase and microorganism strain of the genus Sporolactobacillus.
AU5057093A (en) Simple nucleic acid amplification process

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed